When leukemia, lymphoma, or multiple myeloma returns after initial treatment, specialized salvage pathways, chemotherapy, CAR-T cell therapy, and allogeneic transplant, offer renewed hope. Eligibility for each depends on relapse timing, disease biology, and patient fitness rather than institutional preference. Key Takeaways Salvage chemotherapy re-establishes disease control for chemo-sensitive relapses before high-intensity options like transplant India's indigenous NexCAR19